VNRX vs. VYGR, DSGN, FDMT, LFCR, CCCC, CRDF, SLRN, LRMR, OCGN, and GNFT
Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), 4D Molecular Therapeutics (FDMT), Lifecore Biomedical (LFCR), C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), Acelyrin (SLRN), Larimar Therapeutics (LRMR), Ocugen (OCGN), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry.
VolitionRx vs.
Voyager Therapeutics (NASDAQ:VYGR) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
Voyager Therapeutics received 387 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 67.75% of users gave Voyager Therapeutics an outperform vote while only 14.81% of users gave VolitionRx an outperform vote.
Voyager Therapeutics has a net margin of 15.80% compared to VolitionRx's net margin of -2,321.14%. Voyager Therapeutics' return on equity of 8.33% beat VolitionRx's return on equity.
Voyager Therapeutics has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 12.8% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Voyager Therapeutics had 8 more articles in the media than VolitionRx. MarketBeat recorded 9 mentions for Voyager Therapeutics and 1 mentions for VolitionRx. VolitionRx's average media sentiment score of 0.30 beat Voyager Therapeutics' score of 0.02 indicating that VolitionRx is being referred to more favorably in the news media.
Voyager Therapeutics currently has a consensus target price of $15.72, indicating a potential upside of 272.42%. VolitionRx has a consensus target price of $3.75, indicating a potential upside of 578.73%. Given VolitionRx's higher probable upside, analysts plainly believe VolitionRx is more favorable than Voyager Therapeutics.
Voyager Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
Summary
Voyager Therapeutics beats VolitionRx on 14 of the 19 factors compared between the two stocks.
Get VolitionRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VolitionRx Competitors List
Related Companies and Tools
This page (NYSE:VNRX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free VNRX Stock Alerts